News

November 5, 2018

Myeloma Crowd Launches Online Tool to Help Patients Find Treatment Options, Contribute to Research

News

Myeloma Crowd has launched an online tool called HealthTree, aimed at helping patients with multiple myeloma find the most appropriate therapies for their condition, while boosting research toward a potential cure ... Read more

October 31, 2018

New Compound Safely Halts Advanced Myeloma Progression in Small Pilot Study

News

A new investigational compound targeting a central pathway in cancer development showed promising results in patients with relapsed or refractory multiple myeloma in a small Phase 1/2a pilot trial. ... Read more

October 29, 2018

Trip to Mount Everest’s Base Benefits MMRF-funded Multiple Myeloma Research

News

During a strenuous but spectacular hike, a team including four patients is traversing Nepal’s Khumbu region, encountering some of the world’s tallest mountains, and experiencing Sherpa culture, all in ... Read more

October 26, 2018October 26, 2018

Revlimid Delays Disease Progression in Smoldering Myeloma Patients, Preliminary Trial Results Show

News

Celgene‘s immunomodulatory agent Revlimid (lenalidomide) significantly extended the time until disease progression in patients with smoldering multiple myeloma who were not yet experiencing any symptoms of disease, according to Phase 2/3 results ... Read more

October 24, 2018

Darzalex Add-on Increases Complete Responses After Stem Cell Transplant, Phase 3 Myeloma Trial Shows

News

Adding Darzalex (daratumumab) to the standard pre-transplant therapy for multiple myeloma significantly increased the number of patients showing no signs of cancer after a stem cell transplant, a Phase ... Read more

October 22, 2018

STRO-001 Receives FDA’s Orphan Drug Status for Multiple Myeloma Treatment

News

STRO-001, Sutro Biopharma’s investigational therapy for multiple myeloma, was granted orphan drug designation by the U.S. Food and Drug Administration (FDA). “There is a growing need for new treatment ... Read more

October 19, 2018

Selinexor Granted Priority Review by FDA for Heavily Treated Multiple Myeloma

News

The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its investigational therapy selinexor as a treatment for multiple myeloma patients ... Read more

October 17, 2018

Most Blood Cancer Patients Don’t Fully Understand Their Diagnosis, Survey in England Reveals

News

Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from England’s National Cancer Patient Experience Survey reveals. The figure is much ... Read more

October 15, 2018

FDA Clears ClonoSEQ Assay for Measuring Minimal Residual Disease in Myeloma, Leukemia

News

The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal residual disease (MRD) — the small number of cancer cells that ... Read more

October 12, 2018

Combination of Reolysin, Opdivo, and Standard of Care to Be Tested in Phase 1 Trial for Multiple Myeloma

News

A combination of Oncolytics Biotech’s investigational therapy Reolysin (pelareorep) with anti-cancer medication Opdivo (nivolumab) and standard of care will be tested in patients with relapsed or refractory multiple myeloma. ... Read more